| 李 丽,梁 勇,刘 倩,卞 虎,赵加胜.XELOX方案全身化疗联合门静脉栓塞术+射频消融
治疗晚期结肠癌肝转移的效果[J].现代生物医学进展英文版,2025,(3):550-556. |
| XELOX方案全身化疗联合门静脉栓塞术+射频消融
治疗晚期结肠癌肝转移的效果 |
| Effect of XELOX Regimen Combined with Portal Vein Embolizationand Radiofrequency Ablation in the Treatment of Liver Metastasis of Advanced Colon Cancer |
| Received:November 25, 2024 |
| DOI：10.13241/j.cnki.pmb.2025.03.020 |
| 中文关键词: 晚期结肠癌 肝转移 XELOX化疗方案 门静脉栓塞术 射频消融 疗效 |
| 英文关键词: Advanced colon cancer Liver metastasis XELOX chemotherapy protocol Portal vein embolization Radiofrequency ablation Curative effect |
| 基金项目:江苏省科技发展计划项目(YB202108) |
|
| Hits: 4 |
| Download times: 0 |
| 中文摘要: |
| 摘要 目的：评价XELOX方案全身化疗联合门静脉栓塞术（PVE）+射频消融（RFA）治疗晚期结肠癌肝转移的效果。方法：将本院在2022.7-2024.7收治的120例晚期结肠癌肝转移患者分为对照组和观察组，各60例。两组均予以XELOX方案全身化疗联合PVE治疗，观察组在此基础上采用RFA治疗，评价并比较两组的治疗效果、生存质量等。结果：观察组客观有效率（68.34% vs. 31.67%）、疾病控制率（88.34% vs. 65.00%）均高于对照组（P＜0.05）。治疗后，两组患者血清AFP、CA19-9和CEA水平均低于治疗前，CD3+、CD4+和CD4+/CD8+以及KPS评分、KPS评分升高率均较治疗前高（P＜0.05）。观察组治疗后血清AFP、CA19-9和CEA水平均较对照组低，CD3+、CD4+和CD4+/CD8+以及KPS评分、KPS评分升高率均高于对照组（P＜0.05）。两组均未见明显不良反应。结论：XELOX方案全身化疗联合PVE+ RFA可有效提高晚期结肠癌肝转移治疗效果，提高机体免疫功能和生存质量，降低肿瘤标志物水平，且安全性良好。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the effect of XELOX regimen combined with portal vein embolization (PVE) and radiofrequency ablation (RFA) in the treatment of liver metastasis of advanced colon cancer. Methods: From July 2022 to July 2024, 120 patients with advanced colon cancer liver metastases admitted to our hospital were selected and divided into two groups of 60 cases each according to different treatment methods. Both groups were treated with XELOX regimen combined with PVE, and the observation group was treated with RFA on this basis. The therapeutic effect and quality of life of the two groups were evaluated and compared. Results: The objective effective rate and disease control rate of the observation group were 68.34% and 88.34% respectively, which were higher than those of the matched group (P<0.05). Compared with before treatment, the levels of serum AFP, CA19-9 and CEA in the two groups decreased after treatment(P<0.05), while the decrease in the observation group was greater (P<0.05). After treatment, the CD3+, CD4+ and CD4+/CD8+ in the observation group were higher than those in the matched group(P<0.05), and the KPS score and the increase rate of quality of life were also higher than those in the matched group (P<0.05). Conclusion: XELOX regimen combined with PVE+RFA can effectively improve the clinical efficacy of liver metastasis of advanced colon cancer, reduce the level of serum tumor markers, improve the immune function, improve the quality of life of patients, and have good safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
